Related Experiment Video
Updated: Jan 31, 2026
Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
Published on: January 12, 2024
Vascular protective effects of diabetes medications that mimic or increase glucagon-like peptide-1 activity
Angelica J Motta1, Juraj Koska, Peter Reaven
1Cardiology Department, Phoenix Veterans Affairs Health Care System, Phoenix AZ 85012, USA.
Abstract:
The incidence of type 2 diabetes (T2DM) is increasing rapidly worldwide and is a strong risk factor for cardiovascular disease (CVD) events. Although hyperglycemia is associated with increased CVD, intensive glycemic control with current diabetes medications has failed in recent large clinical trials to reduce macrovascular disease, demonstrating that intensive glucose control alone is insufficient to reduce major CVD events. A new approach to lowering glucose takes advantage of the incretin system and medications that raise or mimic glucagon-like peptide-1 (GLP-1). These agents not only improve glycemic control by mechanisms that minimize hypoglycemia, but also improve lipoprotein profiles, blood pressure control and weight loss. There is also increasing evidence that at least pharmacologic concentrations of GLP-1 or GLP-1 mimetics may improve endothelial function and have direct vascular-protective effects. Importantly, these benefits transpired even before the improvements in weight and overall glucose control occurred. It remains to be seen whether the chronic effects of GLP-1 activity on glucose, CVD risk factors and vascular function will lead to lasting beneficial effects on CVD risk. If preliminary findings on the vasculoprotective effects of GLP-1 agents are validated and confirmed in longitudinal clinical trials, this class of drugs may represent a paradigm shift in the treatment of vascular disease in both patients with diabetes and in non-diabetic individuals at high risk for CVD. Recent patents regarding GLP-1 agents are discussed in this review article.
Insights
Glucagon-like peptide-1 (GLP-1) agents offer a new approach to managing type 2 diabetes (T2DM) and cardiovascular disease (CVD). These drugs improve glucose control and show potential vascular-protective benefits, possibly shifting treatment paradigms.
Area of Science:
- Endocrinology
- Cardiology
- Pharmacology
Background:
- Type 2 diabetes (T2DM) incidence is rising globally, significantly increasing cardiovascular disease (CVD) risk.
- Current intensive glycemic control strategies have not effectively reduced macrovascular events in T2DM patients.
- Existing treatments highlight the insufficiency of glucose control alone for mitigating major CVD events.
Purpose of the Study:
- To explore the role of the incretin system, specifically glucagon-like peptide-1 (GLP-1) agents, in managing T2DM and associated CVD risks.
- To review the multifaceted benefits of GLP-1-based therapies beyond glycemic control.
- To discuss the potential vascular-protective effects and paradigm-shifting implications of GLP-1 mimetics.
Main Methods:
- Review of current literature on GLP-1 agents and their impact on T2DM and CVD.
- Analysis of clinical trial data regarding glycemic control, cardiovascular risk factors, and vascular function.
- Discussion of recent patent landscape for GLP-1-based therapeutics.
Main Results:
- GLP-1 agents improve glycemic control with a low risk of hypoglycemia.
- These agents demonstrate benefits in lipoprotein profiles, blood pressure, and weight management.
- Emerging evidence suggests direct vascular-protective effects of GLP-1, potentially independent of glucose and weight improvements.
Conclusions:
- GLP-1 agents represent a promising therapeutic class for T2DM, offering benefits beyond glucose lowering.
- Potential vascular-protective effects of GLP-1 agents warrant further investigation in longitudinal clinical trials.
- If validated, GLP-1 therapies could revolutionize vascular disease management in diabetic and high-risk non-diabetic individuals.
Related Concept Videos
01:18Increasing Function
01:15Hypoglycemia and Glucagon
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
02:43Peptide Bonds
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
01:23Inhaled Medications